Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.90 |
| ▸ | JAK2 | O60674 | 16/20 | 0.90 |
| ▸ | TYK2 | P29597 | 16/20 | 0.90 |
| ▸ | JAK3 | P52333 | 5/20 | 0.90 |
| ▸ | KDR | P35968 | 2/20 | 0.90 |
| ▸ | STAT1 | P42224 | 1/20 | 0.90 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brepocitinib SCHEMBL17512502 | 0.94 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL17512520 | 0.94 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL22345890 | 0.94 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL24172497 | 0.94 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL31291113 | 0.94 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL24173034 | 0.94 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL24293069 | 0.94 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL24172557 | 0.94 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL24891455 | 0.88 | JAK1 (0.78) | JAK1JAK2TYK2JAK3KDR | |
| Brepocitinib SCHEMBL20767478 | 0.85 | JAK1 (1.00) | JAK1JAK2TYK2JAK3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018155-A1 | NEW CRYSTAL FORM OF P-TOLUENESULFONATE SALT OF DIAZABICYCLIC COMPOUND AND PREPARATION METHOD THEREFOR | CRYSTAL PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018155-A1 | NEW CRYSTAL FORM OF P-TOLUENESULFONATE SALT OF DIAZABICYCLIC COMPOUND AND PREPARATION METHOD THEREFOR | ABCG2, SLC6A11, TST | JAK1 121/4885JAK2 234/4885TYK2 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.